{"id":390315,"date":"2019-12-06T00:00:00","date_gmt":"2019-12-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0007-2019-biopharma-rheumatoid-arthritis-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-04-21T11:25:16","modified_gmt":"2026-04-21T11:25:16","slug":"dlsfim0007-2019-biopharma-rheumatoid-arthritis-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0007-2019-biopharma-rheumatoid-arthritis-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Rheumatoid Arthritis | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>The increasingly crowded\u00a0<abbr title=\"rheumatoid arthritis\">RA<\/abbr>\u00a0market boasts many different targeted agents representing several distinct drug classes, including blockbuster\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors, five non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 biologics (including the second\u00a0<abbr title=\"interleukin\">IL<\/abbr>-6 inhibitor, Regeneron \/ Sanofi\u2019s Kevzara), and three oral\u00a0<abbr title=\"Janus activated kinase\">Jak<\/abbr>\u00a0inhibitors,\u00a0Xeljanz (Pfizer), Olumiant (Eli Lilly), and Rinvoq (AbbVie). The\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors are the most widely prescribed biologics for\u00a0<abbr title=\"rheumatoid arthritis\">RA<\/abbr>\u00a0refractory to conventional\u00a0<abbr title=\"disease-modifying antirheumatic drug\">DMARD<\/abbr>s, and the non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 biologics and\u00a0<abbr title=\"Janus activated kinase\">Jak<\/abbr>\u00a0inhibitors largely compete for use in the\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-refractory population. With the impending entry of additional\u00a0<abbr title=\"Janus activated kinase\">Jak<\/abbr>\u00a0inhibitors (e.g., Gilead \/ Galapagos\u2019s filgotinib) and biosimilars of several\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>\u00a0and non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr>\u00a0biologics, marketers are facing fierce competition and increasing challenges to gain market share.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>\u00a0What are physicians\u2019 preferred\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors, and what factors are influencing this perception? Given the increasingly fragmented\u00a0<abbr title=\"rheumatoid arthritis\">RA<\/abbr>\u00a0market, how likely are physicians to cycle through multiple anti-<abbr title=\"tumor necrosis factor\">TNF<\/abbr>\u00a0agents before progressing to a novel\u00a0<abbr title=\"mechanism of action\">MOA<\/abbr>?<\/li>\n<li>What are physicians\u2019 perceptions of the currently marketed non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitor biologics and oral\u00a0<abbr title=\"Janus activated kinase\">Jak<\/abbr>\u00a0inhibitors, and where do these agents fit in their current treatment approach? Which of these agents has been\/will be most successful in targeting the\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-refractory patient segment?<\/li>\n<li>How will the entry of additional novel oral therapies affect the\u00a0<abbr title=\"rheumatoid arthritis\">RA<\/abbr>\u00a0treatment algorithm, and in which patient segments and lines of treatment will these therapies most likely be used? How will the entry of biosimilars affect the market sales and patient share of currently marketed\u00a0<abbr title=\"rheumatoid arthritis\">RA<\/abbr>\u00a0agents and the entry of emerging therapies?<\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<p><b>Markets covered:<\/b>\u00a0United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/p>\n<p><b>Primary research:<\/b>\u00a027\u00a0country-specific interviews with thought leaders.<\/p>\n<p><b>Epidemiology:<\/b>\u00a0Number of total, diagnosed, and drug-treated prevalent cases of\u00a0<abbr title=\"rheumatoid arthritis\">RA<\/abbr>; number of diagnosed prevalent cases of\u00a0<abbr title=\"rheumatoid arthritis\">RA<\/abbr>\u00a0by severity.<\/p>\n<p><b>Emerging therapies:\u00a0<\/b>Preregistered: 1 drug; Phase III: 3\u00a0drugs; coverage of 11 select early-phase pipeline products.<\/p>\n","protected":false},"template":"","class_list":["post-390315","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390315\/revisions"}],"predecessor-version":[{"id":393440,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390315\/revisions\/393440"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}